Primary Mediastinal B-cell Lymphoma Presenting as Chest Pain in a Young Woman and Treated with EPOCH-R.

Primary mediastinal B-cell lymphoma (PMBCL) is a rare type of diffuse large B-cell lymphoma, constituting 2-4% of non-Hodgkin lymphomas. Here we present a case of PMBCL initially presenting as pleuritic chest pain in an otherwise healthy 33-year-old woman. PMBCL typically presents as a large, fast-growing tumor limited to the mediastinum, making the iliosacral involvement in this case unusual. R-CHOP is the most commonly used chemotherapy regimen, although more aggressive therapies like EPOCH-R can spare the need for consolidative radiation therapy. PMBCL represents one of the greatest diagnostic and therapeutic challenges in malignant hematology.

Approach to Localized Squamous Cell Cancer of the Esophagus.

OPINION STATEMENT: Esophageal cancer is a leading cause of cancer deaths worldwide, with an increasing incidence in recent decades. The majority of esophageal cancers are squamous cell carcinoma. The 5-year survival rate of esophageal squamous cell carcinoma (ESCC) is poor, and there remains globally a pressing need for novel treatments that improve patient outcomes and quality of life. In this review, we discuss management of localized ESCC with an update on relevant newly published literature, including targeted therapy and novel biomarkers. The standard treatment approach for locally advanced, resectable ESCC is currently chemoradiation with or without surgery. Here we discuss different approaches to endoscopic resection, surgery, and radiation therapy. Although the typical chemotherapy regimen is a combination of a platinum with a fluoropyrimidine or paclitaxel, different regimens are being evaluated. With the landscape of immunotherapy rapidly evolving, at the forefront of new treatments for ESCC is immunotherapy and other targeted agents. Ultimately, the treatment approach should be individualized to each patient.

Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report.

Lung cancer incidence is increasing in pregnancy due in part to advanced maternal age. A subset of patients with NSCLC during pregnancy harbor an ALK gene rearrangement. Although ALK inhibitors, such as alectinib, are routinely used to treat ALK-rearranged NSCLC, there are limited safety data regarding use during pregnancy and fetal effects. Here, we report the second case of a patient with metastatic ALK-rearranged lung adenocarcinoma treated with alectinib throughout pregnancy. Notably, the patient had two uncomplicated pregnancies with routine obstetrical and postnatal courses. In this case, alectinib did not seem to affect embryofetal or early childhood development. This does not exclude undetectable or delayed toxic effects, and additional studies are needed to further reveal the safety of alectinib treatment during pregnancy.

Case report: gastric plasmacytoma resistant to radiation therapy.

Plasma cell neoplasms are a group of diseases involving the malignant proliferation of plasma cells. One common type of plasma cell neoplasm is multiple myeloma, which typically occurs diffusely in the bone marrow. It can manifest with a variety of presentations, including bone pain, fractures, anemia, infection, hypercalcemia, and renal failure. A less common type of plasma cell neoplasm is the solitary plasmacytoma, which is a local proliferation of plasma cells in the bone or extramedullary tissues. They rarely recur after local radiation therapy.An 83-year-old woman was noted on routine labwork to have elevated total serum protein, and serum immunofixation confirmed IgG/Kappa paraprotein. There was no evidence of end-organ damage characteristic of myeloma: hypercalcemia, renal dysfunction, anemia, or bone lesions. She was diagnosed with monoclonal gammopathy of undetermined significance and placed on observation. Seven years later, she developed mild anemia and an increasing M spike. No abnormalities were found on bone marrow biopsy apart from mildly increased plasma cell proliferation (7-10% of total cells). A PET scan showed increased gastric uptake, concerning for possible gastric malignancy. Upper gastrointestinal endoscopic ultrasound revealed extrinsic compression of the stomach fundus and body due to a 40 mm mass and associated adenopathy. Pathology revealed a kappa-restricted plasma cell neoplasm positive for CD138.The patient underwent radiation therapy localized to the gastric area. Subsequent evaluation revealed a persistent gastric mass. Attempted biopsy resulted in a gastrointestinal bleed, rendering her unable to undergo treatment with lenalidomide and aspirin. She is currently undergoing chemotherapy with bortezomib, cyclophosphamide, and dexamethasone. The case illustrates the potential diversity of plasma cell dyscrasia clinical manifestations. Gastric plasmacytomas are an uncommon type of extramedullary plasmacytoma, particularly rare when resistant to radiation therapy.